Talaulikar, Dipti; Tam, Constantine S; Joshua, Douglas; Ho, Joy Phoebe; Szer, Jeff; Quach, Hang; Spencer, Andrew; Harrison, Simon; Mollee, Peter; Roberts, Andrew W; Horvath, Noemi; Lee, Cindy; Zannettino, Andrew; Brown, Ross; Augustson, Bradley; Jaksic, Wilfrid; Gibson, John; Kalff, Anna; Johnston, Anna; Trotman, Judith; Kalro, Akash; Grigoriadis, George; Ward, Chris; Prince, H Miles

Author(s)

Talaulikar, Dipti

Tam, Constantine S

Joshua, Douglas

Ho, Joy Phoebe

Szer, Jeff

Quach, Hang

Spencer, Andrew

Harrison, Simon

Mollee, Peter

Roberts, Andrew W

Horvath, Noemi

Lee, Cindy

Zannettino, Andrew

Brown, Ross

Augustson, Bradley

Jaksic, Wilfrid

Gibson, John

Kalff, Anna

Johnston, Anna

Trotman, Judith

Kalro, Akash

Grigoriadis, George

Ward, Chris

Prince, H Miles

Publication Date

2017-01-01

Abstract

Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is seen in >90% of cases, within the diagnostic criteria for WM. While treatment of WM has often been considered together with other indolent B cell lymphomas, there are unique aspects of WM management that require specific care. These include the unreliability of IgM and paraprotein measurements in monitoring patients prior to and after treatment, the lack of correlation between disease burden and symptoms and rituximab-induced IgM flare. Moreover, while bendamustine and rituximab has recently been approved for reimbursed frontline use in WM in Australia, other regimens, including ibrutinib- and bortezomib-based treatments, are not funded, requiring tailoring of treatment to the regional regulatory environment. The Medical and Scientific Advisory Group of the Myeloma Foundation Australia has therefore developed clinical practice guidelines with specific recommendations for the work-up and therapy of WM to assist Australian clinicians in the management of this disease.

Affiliation

Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.. Australian National University, Canberra, Australian Capital Territory, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia..

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Melbourne, Victoria, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.. School of Medicine, University of Queensland, Brisbane, Queensland, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Melbourne, Victoria, Australia.. Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.. Faculty of Health, University of Tasmania, Hobart, Tasmania, Australia..

Department of Haematology, Concord Hospital, Sydney, New South Wales, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Darwin Hospital, Darwin, Northern Territory, Australia..

Department of Haematology, Southern Health, Melbourne, Victoria, Australia.. Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.. Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia..

Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia..

Citation

Internal medicine journal 2017-01; 47(1): 35-49

Pubmed ID

https://pubmed.ncbi.nlm.nih.gov/28076910/?otool=iaurydwlib

Link

https://hdl.handle.net/10137/5293

Subject

Waldenström macroglobulinaemia

ibrutinib, bendamustine

lymphoplasmacytic lymphoma

monoclonal gammopathy of undetermined significance

rituximab

MESH subject

Advisory Committees

Antineoplastic Agents

Australia

Bendamustine Hydrochloride

Bone Marrow

Bortezomib

Humans

Immunoglobulin M

Mutation

Myeloid Differentiation Factor 88

Plasma Cells

Practice Guidelines as Topic

Pyrazoles

Pyrimidines

Rituximab

Societies, Medical

Waldenstrom Macroglobulinemia

Title

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Type of document

Journal Article

Entity Type

Publication

Author(s)	Talaulikar, Dipti Tam, Constantine S Joshua, Douglas Ho, Joy Phoebe Szer, Jeff Quach, Hang Spencer, Andrew Harrison, Simon Mollee, Peter Roberts, Andrew W Horvath, Noemi Lee, Cindy Zannettino, Andrew Brown, Ross Augustson, Bradley Jaksic, Wilfrid Gibson, John Kalff, Anna Johnston, Anna Trotman, Judith Kalro, Akash Grigoriadis, George Ward, Chris Prince, H Miles
Publication Date	2017-01-01
Abstract	Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is seen in >90% of cases, within the diagnostic criteria for WM. While treatment of WM has often been considered together with other indolent B cell lymphomas, there are unique aspects of WM management that require specific care. These include the unreliability of IgM and paraprotein measurements in monitoring patients prior to and after treatment, the lack of correlation between disease burden and symptoms and rituximab-induced IgM flare. Moreover, while bendamustine and rituximab has recently been approved for reimbursed frontline use in WM in Australia, other regimens, including ibrutinib- and bortezomib-based treatments, are not funded, requiring tailoring of treatment to the regional regulatory environment. The Medical and Scientific Advisory Group of the Myeloma Foundation Australia has therefore developed clinical practice guidelines with specific recommendations for the work-up and therapy of WM to assist Australian clinicians in the management of this disease.
Affiliation	Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.. Australian National University, Canberra, Australian Capital Territory, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Melbourne, Victoria, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.. School of Medicine, University of Queensland, Brisbane, Queensland, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Melbourne, Victoria, Australia.. Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.. Faculty of Health, University of Tasmania, Hobart, Tasmania, Australia.. Department of Haematology, Concord Hospital, Sydney, New South Wales, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Darwin Hospital, Darwin, Northern Territory, Australia.. Department of Haematology, Southern Health, Melbourne, Victoria, Australia.. Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.. Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia..
Citation	Internal medicine journal 2017-01; 47(1): 35-49
Pubmed ID	https://pubmed.ncbi.nlm.nih.gov/28076910/?otool=iaurydwlib
Link	https://hdl.handle.net/10137/5293
Subject	Waldenström macroglobulinaemia ibrutinib, bendamustine lymphoplasmacytic lymphoma monoclonal gammopathy of undetermined significance rituximab
MESH subject	Advisory Committees Antineoplastic Agents Australia Bendamustine Hydrochloride Bone Marrow Bortezomib Humans Immunoglobulin M Mutation Myeloid Differentiation Factor 88 Plasma Cells Practice Guidelines as Topic Pyrazoles Pyrimidines Rituximab Societies, Medical Waldenstrom Macroglobulinemia
Title	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Type of document	Journal Article
Entity Type	Publication

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Files: